Table 2

Clinical cure rates at test-of-cure visit


Tigecycline
Imipenem/cilastatin
Difference Tigecycline-Imipenem/cilastatin
Test for Noninferiority
Test for Differences


Population
N
% (95% CI)
N
% (95% CI)
% (95% CI)
P value


CE
282/341
82.7 (78.3, 86.6)
295/351
84.0 (79.8, 87.7)
-1 (-7.2, 4.5)
<0.0001
0.70
     Overall






-1 (-6.9, 4.2)*
c-mITT
303/408
74.3 (69.7, 78.4)
317/399
79.4 (75.1, 83.3)
-5 (-11.2, 0.0)
<0.0001
0.00
     Overall






-5 (-11.0, 0.0)
ME
199/247
80.6 (75.1, 85.3)
210/255
82.4 (77.1, 86.8)
-1.8 (-9.0, 5.4)
0.0001
0.6892
     Monomicrobial
80/89
89.9 (81.7, 95.3)
92/104
88.5 (80.7, 93.9)
1.4 (-8.7, 11.0)


     Polymicrobial
119/158
75.3 (67.8, 81.8)
118/151
78.1 (70.7, 84.5)
-2.8 (-12.6, 7.1)


     Overall






-1.7 (-8.4, 5.1)*
m-mITT
227/309
73.5 (68.2, 78.3)
244/312
78.2 (73.2, 82.7)
-4.7 (-11.8, 2.3)
0.0019
0.1976
     Monomicrobial
96/121
79.3 (71.0, 86.2)
109/128
85.2 (77.8, 90.8)
-5.8 (-15.9, 4.3)


     Polymicrobial
131/188
69.7 (62.6, 76.2)
135/184
73.4 (66.4, 79.6)
-3.7 (-13.1, 5.9)


     Overall






-4.3 (-11.0, 2.5)*

*Adjusted difference and its 95%CI are calculated from a generalized linear model with a binomial probability function and an identity link.

Oliva et al. BMC Infectious Diseases 2005 5:88   doi:10.1186/1471-2334-5-88